The effect of mirabegron on bladder blood flow in a rat model of bladder outlet obstruction.
Animal model
Bladder ischemia
Bladder outlet obstruction
β3-Adrenergic receptor agonists
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
31
07
2019
accepted:
28
08
2019
pubmed:
31
10
2019
medline:
10
4
2021
entrez:
31
10
2019
Statut:
ppublish
Résumé
To evaluate the effects of mirabegron on bladder blood flow in a rat model of bladder outlet obstruction (BOO). Adult female Sprague-Dawley rats were divided into three groups based on whether they underwent a sham operation (sham group) or an operation to establish partial BOO (BOO and BOO + mirabegron groups). The BOO + mirabegron group was treated with mirabegron (0.3 mg/kg/h, subcutaneously) for 14 days. Subsequently, we performed continuous cystometry, bladder blood flow measurements with a 2D laser blood flow imager, hematoxylin-eosin staining of the bladder tissue, and malondialdehyde (MDA) measurements in the bladder tissue. Cystometry revealed significantly higher peak pressure, more residual urine volume, and lower voiding efficiency in the BOO and BOO + mirabegron groups than in the sham group. The BOO + mirabegron group had significantly fewer non-voiding contractions (NVCs) than the BOO group, while the latter had more frequent NVCs than the sham group. The BOO and BOO + mirabegron groups had significantly decreased bladder blood flow than the sham group, whereas the BOO + mirabegron group showed significantly increased bladder blood flow than the BOO group. The bladder tissue in the BOO group contained more hypertrophic detrusor muscle compared to the sham group, while mirabegron treatment suppressed detrusor hypertrophy. The MDA levels were significantly higher in the BOO group than in the BOO + mirabegron and sham groups. Mirabegron treatment significantly improved BOO-induced bladder dysfunction through the amelioration of bladder blood flow.
Identifiants
pubmed: 31664511
doi: 10.1007/s00345-019-02939-9
pii: 10.1007/s00345-019-02939-9
doi:
Substances chimiques
Acetanilides
0
Adrenergic beta-3 Receptor Agonists
0
Thiazoles
0
mirabegron
MVR3JL3B2V
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2021-2027Subventions
Organisme : Astellas Pharma
ID : BE-INCL-001
Références
Abrams P, Cardozo L, Fall M et al (2003) The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 61:37
doi: 10.1016/S0090-4295(02)02243-4
Milsom I, Abrams P, Cardozo L et al (2001) How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 87:760
doi: 10.1046/j.1464-410x.2001.02228.x
Irwin DE, Milsom I, Hunskaar S et al (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50:1306
doi: 10.1016/j.eururo.2006.09.019
Ge TJ, Vetter J, Lai HH (2017) Sleep disturbance and fatigue are associated with more severe urinary incontinence and overactive bladder symptoms. Urology 109:67
doi: 10.1016/j.urology.2017.07.039
Jayadevappa R, Chhatre S, Newman DK et al (2018) Association between overactive bladder treatment and falls among older adults. Neurourol Urodyn 37(8):2688–2694
doi: 10.1002/nau.23719
Andersson KE, Nomiya M, Yamaguchi O (2015) Chronic pelvic ischemia: contribution to the pathogenesis of lower urinary tract symptoms (LUTS): a new target for pharmacological treatment? Low Urin Tract Symptoms 7:1
doi: 10.1111/luts.12084
Majima T, Yamamoto T, Funahashi Y et al (2017) Effect of naftopidil on bladder microcirculation in a rat model of bladder outlet obstruction. Low Urin Tract Symptoms 9:111
doi: 10.1111/luts.12119
Inoue S, Saito M, Tsounapi P et al (2012) Effect of silodosin on detrusor overactivity in the male spontaneously hypertensive rat. BJU Int 110:E118
doi: 10.1111/j.1464-410X.2011.10814.x
Gotoh D, Torimoto K, Tatsumi Y et al (2018) Tadalafil, a phosphodiesterase type 5 inhibitor, improves bladder blood supply and restores the initial phase of lower urinary tract dysfunction in diabetic rats. Neurourol Urodyn 37:666
doi: 10.1002/nau.23372
Yamaguchi O, Chapple CR (2007) Beta3-adrenoceptors in urinary bladder. Neurourol Urodyn 26:752
doi: 10.1002/nau.20420
Yamaguchi O, Marui E, Kakizaki H et al (2014) Phase III, randomised, double-blind, placebo-controlled study of the 3-adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder. BJU Int 113:951
doi: 10.1111/bju.12649
Kelleher C, Hakimi Z, Zur R et al (2018) Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis. Eur Urol 74:324
doi: 10.1016/j.eururo.2018.03.020
Okutsu H, Matsumoto S, Hanai T, Noguchi Y, Fujiyasu N, Ohtake A, Suzuki M, Sato S, Sasamata M, Uemura H, Takashi K (2010) Effects of tamsulosin on bladder blood flow and bladder function in rats with bladder outlet obstruction. Urology 75:235
doi: 10.1016/j.urology.2009.05.045
Kawai Y, Oka M, Kyotani J et al (2012) Effect of the phytotherapeutic agent Eviprostat on the bladder in a rat model of bladder overdistension/emptying. Neurourol Urodyn 32:1031–1037
doi: 10.1002/nau.22350
Shafei MN, Niazmand S, Enayatfard L et al (2013) Pharmacological study of cholinergic system on cardiovascular regulation in the cuneiform nucleus of rat. Neurosci Lett 549:12
doi: 10.1016/j.neulet.2013.05.046
Mannikarottu AS, Disanto ME, Zderic SA et al (2006) Altered expression of thin filament-associated proteins in hypertrophied urinary bladder smooth muscle. Neurourol Urodyn 25:78
doi: 10.1002/nau.20121
Greenland JE, Brading AF (2001) The effect of bladder outflow obstruction on detrusor blood flow changes during the voiding cycle in conscious pigs. J Urol 165:245
doi: 10.1097/00005392-200101000-00072
Levin RM, Levin SS, Zhao Y et al (1997) Cellular and molecular aspects of bladder hypertrophy. Eur Urol 32(Suppl 1):15
pubmed: 9218938
Valko M, Leibfritz D, Moncol J et al (2007) Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 39:44
doi: 10.1016/j.biocel.2006.07.001
Masuda H et al (2007) Reactive oxygen species mediate detrusor overactivity via sensitization of afferent pathway in the bladder of anaesthetized rats. BJU Int 101:775
doi: 10.1111/j.1464-410X.2007.07310.x
Frazier EP, Peters SLM, Braverman AS et al (2008) Signal transduction underlying the control of urinary bladder smooth muscle tone by muscarinic receptors and β-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol 377:449–462
doi: 10.1007/s00210-007-0208-0
Greenland JE et al (2000) The effect of bladder outlet obstruction on tissue oxygen tension and blood flow in the pig bladder. BJU Int 85(9):1109–1114
doi: 10.1046/j.1464-410x.2000.00611.x
Belge C, Hammond J, Dubois-Deruy E et al (2014) Enhanced expression of beta3-adrenoceptors in cardiac myocytes attenuates neurohormone-induced hypertrophic remodeling through nitric oxide synthase. Circulation 129:451
doi: 10.1161/CIRCULATIONAHA.113.004940
Hatanaka T, Ukai M, Watanabe M et al (2013) Effect of mirabegron, a novel beta3-adrenoceptor agonist, on bladder function during storage phase in rats. Naunyn Schmiedebergs Arch Pharmacol 386:71
doi: 10.1007/s00210-012-0814-3
Kitta T, Kanno Y, Chiba H et al (2018) Benefits and limitations of animal models in partial bladder outlet obstruction for translational research. Int J Urol 25:36
doi: 10.1111/iju.13471
Pontari MA, Ruggieri MR (1999) Sex differences and role of nitric oxide in blood flow of canine urinary bladder. Am J Physiol 276:R407
pubmed: 9950918